

administered. Providing multiple and varied antibiotic-related informational messages may increase knowledge of appropriate antibiotic prescribing and decrease patient demand for antibiotics.

Extemporaneous drugs used in the treatment of acne for example has shown a combined (anti inflammatory, antihistamine, antimicrobial) and drying effects wincing enhance rapid recovery without relapse.

## CLINICAL AND PHARMACEUTICAL ANALYSIS OF PLESTAZOLE USING FOR THE PERIPHERAL ARTERIAL DISEASES TREATMENT

Naumenko Ye. D.

Scientific supervisor: Dobrova V. E.

National University of Pharmacy, Kharkiv, Ukraine

rashevskayanasty@gmail.com

**Introduction.** Cilostazol is an FDA-approved drug for the treatment of intermittent claudication (recommendation level I). According to the recommendations of the European Society of Vascular Surgeons 2015, cilostazol (100 mg 2 g / day) is used in patients with intermittent claudication without concomitant heart failure for a 3-month course to increase the distance of painless walking.

**Aim** is to investigate the need for the health care system of Ukraine in Plestazol (INN - cilostazol) in terms of disease prevalence and morbidity and the likely impact of drugs on the course of the disease, illness and condition

**Materials and methods.** We analyzed sales volumes (retail sales data, hospital purchases were less than 1%) INN cilostazol in 2019 on the «Morion» (data included dosages of 50 mg and 100 mg and differed in the number of tablets in the package). Calculations of the target population also were carried out according to the website <http://www.ukrstat.gov.ua>.

**Results and discussion.** We recalculated and found that when using cilostazol at a dose of 100 mg 2 times a day for 3 months (as indicated in the instructions for medical use), the number of patients using cilostazol is 20758. The need for 1 patient for 1 year (course treatment for 24 weeks, as indicated in a clinical trial, Dawson, 2000) is 5.6 packs (cilostazol 100 mg № 60). As there are no accurate data on the prevalence of intermediate lameness and morbidity in Ukraine, we estimate the number of patients is 58,962 patients, which require 389,149 packs of cilostazol 100 mg № 60 per year. Assessing the likely impact of cilostazol on disease, disease, and condition, it should be noted that of all the drugs used for intermittent claudication, only cilostazol has an effect on primary and secondary stroke prevention and transient ischemic attack, as reflected in the budgetary impact. The elderly population, or population 65 + in Ukraine as of January 1, 2020 was 9,821.1 thousand people. According to scientific publications, diseases of the arteries of the lower extremities in the elderly are 6% of 9,821,100 - 589,626 people, of whom 10-35% are intermittent claudication.

**Conclusions.** The search showed that the most common is stage II - "intermittent claudication", but after 5 years it leads to heart attack, stroke and other complications. After our analysis we selected that the lower limit for the need for the health care system of Ukraine in Plestazol is 58,962 patients.